Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Consulting agrmnt
Immunome Inc. (IMNM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Entered into consulting agreement
Docs: "CERTIFICATE OF MERGER MERGING IBIZA MERGER SUB, INC., A DELAWARE CORPORATION WITH AND INTO MORPHIMMUNE INC., A DELAWARE CORPORATION Pursuant to Title 8, Section 251 of the General Corporation Law of the State of Delaware Pursuant to Title 8, Section 251 of the Delaware General Corporation Law , the undersigned corporation executed the following Certificate of Merger: FIRST: The name of the surviving corporation is Morphimmune Inc., a Delaware corporation , and the name of the corporation being merged into this surviving corporation is Ibiza Merger Sub, Inc., a Delaware corporation . SECOND: An Agreement and Plan of Merger and Reorganization, dated June 29, 2023 , by and among Immunome, Inc., a Delaware corporation, Merger Sub and the Company, setting forth the terms and conditions of the m...",
"CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNOME, INC. It is hereby certified that: FIRST : The name of the corporation is Immunome, Inc. . SECOND : The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by adding new Article IX as follows: IX.",
"CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNOME, INC.",
"Immunome and Morphimmune Announce Successful Completion of Merger with"
08/09/2023 8-K Quarterly results
Docs: "Immunome Reports Second Quarter 2023 Financial Results Exton, PA – August 9, 2023 – Immunome, Inc. , a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We believe combining Immunome and Morphimmune’ s technologies represents a major step in our long-term strategy of creating a preeminent oncology therapeutics company,” stated Purnanand Sarma, PhD, President and CEO of Immunome. “Targeted cancer therapies have made great strides in recent years, and the possible synergy between Morphimmune’ s Targeted Effector Platform and Immunome’ s proprietary Discovery Engine presents an..."
07/05/2023 8-K Investor presentation
Docs: "MORPHIMMUNE + IMMUNOME 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Morphimmune, Inc. and Immunome, Inc. or any person on their behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. No Representations and Warranties This presentation is being distributed solely to qualified institutional buyers and accredited investors with sufficient knowledge and experience in investment, financial and business matters and the capability to conduct their own due diligence investiga..."
06/29/2023 8-K Investor presentation
Docs: "AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"Schedule A",
"Schedule A",
"Lock-Up Agreement",
"SUBSCRIPTION AGREEMENT",
"EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT is entered into as of June 28, 2023 between Immunome, Inc., a Delaware corporation , and Clay B. Siegall, Ph.D. . R E C I T A L S WHEREAS, Executive is currently the Chief Executive Officer of Morphimmune Inc., a Delaware corporation , pursuant to a certain Executive Employment Agreement dated as of January 4, 2023 ; WHEREAS, Morphimmune, the Company and Ibiza Merger Sub, Inc., a wholly owned subsidiary of Immunome , are parties to a certain Agreement and Plan of Merger and Reorganization dated as of June 29, 2023 ;    WHEREAS, upon consummation of the merger of Merger Sub into Morphimmune, as contemplated by the Merger Agreement , Morphimmune would become a wholly owned subsidiary of the Company ;   WHERE...",
"Investor Contact",
"CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Morphimmune, Inc. and Immunome, Inc. or any person on their behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. No Representations and Warranties This presentation is being distributed solely to qualified institutional buyers and accredited investors with sufficient knowledge and experience in investment, financial and business matters and the capab..."
05/05/2023 8-K Quarterly results
Docs: "Immunome Reports First Quarter 2023 Financial Results"
03/16/2023 8-K Quarterly results
Docs: "Immunome Reports Fourth Quarter and Full Year 2022 Financial Results EXTON, Pa. – March 16, 2023 - Immunome, Inc. , a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. “Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response ,” stated Purnanand Sarma, Ph.D., President and CEO of Immunome. “We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our pipeline, includ..."
01/30/2023 8-K Investor presentation
Docs: "2 Disclaimers and Forward - Looking Statements Copyright © 2023 Immunome, Inc. All rights reserved. This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and infectious disease programs and platform, execution of our regulatory, clinical and strategic plans, therapeutic potential and benefits of our programs and anticipated upcoming milestones for our programs, as well as the timing and progress of each of the foregoing matters. Forward - looking..."
01/06/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Immunome:"
01/06/2023 8-K Investor presentation
Docs: "Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright © 2023 Immunome, Inc. All rights reserved."
11/15/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
09/02/2022 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex...
Docs: "Series B Warrants to Purchase Shares of Common Stock dated as of April 28, 2021"
08/05/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/28/2022 8-K Quarterly results
Docs: "Immunome Reports Fourth Quarter and Full Year 2021 Financial Results"
03/11/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
01/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
11/29/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "- IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern"
10/18/2021 8-K Investor presentation
Docs: "Harnessing the Human Memory B Cell Response To Develop Antibody"
09/21/2021 8-K Investor presentation
Docs: "Harnessing the Human Memory B Cell Response To Develop Antibody"
09/08/2021 8-K Quarterly results
08/05/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT"
07/20/2021 8-K Investor presentation
Docs: "Presentation (furnished herewith)",
"Immunome Media Contact"
06/17/2021 8-K Quarterly results
06/01/2021 8-K Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders  Interactive ...
05/20/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "APPENDIX A",
"Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern"
05/12/2021 8-K Quarterly results
Docs: "Immunome Reports First Quarter 2021 Financial Results"
04/26/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy